Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

Joe LaVorgna was asked on MSNBC' (10/22, 1.31M) about reports that Senate Majority Leader McConnell will not support a package before the election. LaVorgna said, "I would say people are trying to drive a wedge on the Republican side and I don't think that's particularly fair." LaVorgna was also intervi

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

832cd5a?pubid=fbi> (10/22, 1.3IM) EFTA00136969 about reports that Senate Majority Leader McConnell will not support a package before the election. LaVorgna said, "I would say people are trying to drive a wedge on the Republican side and I don't think that's particularly fair." LaVorgna was also intervi

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

Joe LaVorgna was asked on MSNBCVi (10/22, 1.31M) about reports that Senate Majority Leader McConnell will not support a package before the election. LaVorgna said, "I would say people are trying to drive a wedge on the Republican side and I don't think that's particularly fair." LaVorgna was also intervi